UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of |
| (Commission |
| (I.R.S. Employer |
incorporation) |
| File Number) |
| Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 10, 2026, Tactile Systems Technology, Inc. (“we,” “us,” and “our”) issued a press release disclosing our results of operations and financial condition for our most recently completed fiscal quarter. A copy of the press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in that filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT INDEX
Exhibit |
| Description | |||
99.1 |
| ||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TACTILE SYSTEMS TECHNOLOGY, INC. | |||
Date: August 10, 2026 | By: | /s/ Elaine M. Birkemeyer | |
Elaine M. Birkemeyer | |||
Chief Financial Officer | |||
Exhibit 99.1
Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results
MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2026.
Second Quarter 2026 Summary and Recent Business Highlights:
| ● | Total revenue increased 9% year-over-year to $85.7 million |
| ● | Gross margin expanded to 76% from 75% in Q2 2025 |
| ● | Net income increased to $7.8 million from $3.2 million in Q2 2025 |
| ● | Adjusted EBITDA increased to $11.4 million from $7.7 million in Q2 2025 |
| ● | Entered into an exclusive U.S. distribution agreement with ElastiMed, Inc. to distribute the MyoSleeve™ Wearable Compression Device to Veterans and active-duty service members and their dependents |
| ● | Commercially launched the next-generation AffloVest Airway Clearance Therapy system |
| ● | Repurchased $5.3 million of stock under the Company’s share repurchase program |
| ● | Publication of six-month clinical results from the Company's randomized controlled trial evaluating Flexitouch® Plus for the treatment of head and neck cancer-related lymphedema |
“We are encouraged by our strong momentum in the second quarter. We delivered solid revenue growth, expanded gross margin, and generated meaningful adjusted EBITDA, underscoring the strength of our business model and our team’s disciplined execution,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “Our core lymphedema business remains healthy and our view of the long-term opportunity for AffloVest to be a leading high frequency chest wall oscillation technology therapy is unchanged despite the impact of a temporary inventory management dynamic related to the launch of our next-generation AffloVest system during the quarter.”
Ms. Dodd continued, “Operationally, we made tangible progress furthering our broader strategy. We advanced integration activities for LymphaTech, which expands our portfolio across the lymphedema care continuum, launched our next-generation AffloVest system, and secured exclusive Department of Veterans Affairs and Department of Defense distribution rights for MyoSleeve. These product and capability investments strengthen and broaden our patient reach and market expansion, enabling diagnostic and therapy options for patients and providers. With a clear growth and leverage strategy and a differentiated portfolio, we believe Tactile Medical is well-positioned for sustainable, profitable growth in the years ahead.”
Second Quarter 2026 Financial Results
Total revenue in the second quarter of 2026 increased $6.8 million, or 9%, to $85.7 million, compared to $78.9 million in the second quarter of 2025. The increase in total revenue was attributable to an increase of $7.7 million, or 12%, in sales and rentals of the lymphedema product line, partially offset by a decrease of $0.9 million, or 7%, in sales of the airway clearance product line, due to temporary inventory management dynamics associated with the launch of the Company’s next-generation AffloVest system among a few large DME providers during the quarter.
Gross profit in the second quarter of 2026 increased $6.6 million, or 11%, to $65.3 million, compared to $58.8 million in the second quarter of 2025. Gross margin was 76% of revenue, compared to 75% of revenue in the second quarter of 2025. Gross margin improvement reflected continued operating execution and product cost discipline.
Operating expenses in the second quarter of 2026 increased $3.8 million, or 7%, to $58.5 million, compared to $54.7 million in the second quarter of 2025. The increase primarily reflected continued investments to support long-term growth initiatives.
Operating income was $6.8 million in the second quarter of 2026, compared to $4.1 million in the second quarter of 2025.
Income tax benefit was $0.4 million in the second quarter of 2026, compared to an income tax expense of $1.3 million in the second quarter of 2025.
Net income in the second quarter of 2026 was $7.8 million, or $0.34 per diluted share, compared to $3.2 million, or $0.14 per diluted share, in the second quarter of 2025.
Weighted average shares used to compute diluted net income per share were 23.1 million and 23.2 million for the second quarters of 2026 and 2025, respectively.
Adjusted EBITDA was $11.4 million in the second quarter of 2026, compared to $7.7 million in the second quarter of 2025, reflecting revenue growth, gross margin expansion and disciplined expense management.
First Six Months 2026 Financial Results
Total revenue for the six months ended June 30, 2026, increased $20.8 million, or 15%, to $161.0 million, compared to $140.2 million for the six months ended June 30, 2025. The increase in total revenue was attributable to an increase of $19.3 million, or 17%, in sales and rentals of the lymphedema product line and an increase of $1.5 million, or 6%, in sales of the airway clearance product line for the six months ended June 30, 2026, compared to the six months ended June 30, 2025.
Net income for the six months ended June 30, 2026, was $6.0 million, or $0.26 per diluted share, compared to $0.2 million, or $0.01 per diluted share, for the six months ended June 30, 2025.
Weighted average shares used to compute diluted net income per share were 23.1 million and 23.7 million for the six months ended June 30, 2026 and 2025, respectively.
Adjusted EBITDA was $15.1 million in the six months ended June 30, 2026, compared to $7.4 million in the six months ended June 30, 2025.
Balance Sheet Summary
As of June 30, 2026, the Company had $69.9 million in cash and no outstanding borrowings under its credit agreement, compared to $83.4 million in cash and no outstanding borrowings under its credit agreement as of December 31, 2025. The Company repurchased $5.3 million of its stock during the second quarter under its repurchase program. As of June 30, 2026, $18.7 million remained available under the Company’s $25.0 million share repurchase program, which expires November 3, 2027.
2026 Financial Outlook
The Company is updating its 2026 financial outlook and now expects full year 2026 total revenue in the range of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year.
The Company continues to expect full year 2026 adjusted EBITDA in the range of $49 million to $51 million, compared to adjusted EBITDA of $44.8 million in 2025.
The revised revenue outlook reflects continued confidence in the Company's lymphedema product line, partially offset by a more conservative view of airway clearance product line ordering patterns as certain DME providers work through near-term elevated inventory levels related to the launch of the Company’s next-generation AffloVest system.
Conference Call
Management will host a conference call with a question-and-answer session at 5:00 p.m. Eastern Time on August 10, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13761142. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13761142. The webcast will be archived at investors.tactilemedical.com.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic respiratory conditions by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements, including guidance for the full year 2026. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the Company’s ability to obtain reimbursement from third-party payers for its products; adverse economic conditions, including
inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; price increases for supplies and components; wage and component price inflation; loss of a key supplier or other supply chain disruptions; entry of new competitors and/or competitive products; compliance with and changes in federal, state and local government laws and regulations; technological obsolescence of, or quality issues with, the Company’s products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
This press release includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted EBITDA in this release represents net income, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus litigation-related costs, plus executive transition costs, and plus acquisition and integration costs. Reconciliation of this non-GAAP financial measure to its most directly comparable GAAP measure is included in this press release.
This non-GAAP financial measure is presented because the Company believes it is a useful indicator of its operating performance. Management uses this measure principally as a measure of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes this measure is useful to investors as supplemental information and because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes this non-GAAP financial measure is useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.
The non-GAAP financial measure presented in this release should not be considered as an alternative to, or superior to, its respective GAAP financial measure, as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of
non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
Investor Inquiries:
Sam Bentzinger
Gilmartin Group
Tactile Systems Technology, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
(Unaudited) | ||||||
| | June 30, | | December 31, | ||
(In thousands, except share and per share data) | | 2026 | | 2025 | ||
Assets | | | | | | |
Current assets | | | | | | |
Cash | | $ | 69,853 | | $ | 83,446 |
Accounts receivable, net | |
| 43,140 | |
| 43,876 |
Net investment in leases | |
| 14,927 | |
| 15,754 |
Inventories | |
| 16,845 | |
| 14,025 |
Income taxes receivable | |
| 912 | |
| — |
Prepaid expenses and other current assets | |
| 11,925 | |
| 8,066 |
Total current assets | |
| 157,602 | |
| 165,167 |
Non-current assets | | | | | | |
Property and equipment, net | |
| 5,849 | |
| 5,117 |
Right of use operating lease assets | |
| 12,553 | |
| 13,798 |
Intangible assets, net | |
| 44,747 | |
| 39,167 |
Goodwill | | | 39,554 | | | 31,063 |
Deferred income taxes | |
| 8,703 | |
| 9,783 |
Other non-current assets | |
| 10,660 | |
| 9,847 |
Total non-current assets | |
| 122,066 | |
| 108,775 |
Total assets | | $ | 279,668 | | $ | 273,942 |
Liabilities and Stockholders' Equity | | | | | | |
Current liabilities | | | | | | |
Accounts payable | | $ | 7,923 | | $ | 4,968 |
Accrued payroll and related taxes | |
| 15,615 | |
| 19,378 |
Accrued expenses | |
| 8,423 | |
| 8,531 |
Income taxes payable | |
| — | |
| 1,428 |
Operating lease liabilities | |
| 3,095 | |
| 3,195 |
Other current liabilities | |
| 3,197 | |
| 3,457 |
Total current liabilities | |
| 38,253 | |
| 40,957 |
Non-current liabilities | | | | | | |
Accrued warranty reserve, non-current | |
| 1,079 | |
| 1,045 |
Income taxes payable, non-current | |
| 370 | |
| 275 |
Operating lease liabilities, non-current | | | 11,267 | |
| 12,763 |
Other non-current liabilities | | | 4,863 | | | — |
Total non-current liabilities | |
| 17,579 | |
| 14,083 |
Total liabilities | |
| 55,832 | |
| 55,040 |
Stockholders’ equity: | | | | | | |
Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of June 30, 2026 and December 31, 2025 | |
| — | |
| — |
Common stock, $0.001 par value, 300,000,000 shares authorized; 22,701,241 shares issued and outstanding as of June 30, 2026; 22,438,926 shares issued and outstanding as of December 31, 2025 | |
| 23 | |
| 22 |
Additional paid-in capital | |
| 162,851 | |
| 163,940 |
Retained earnings | |
| 60,962 | |
| 54,940 |
Total stockholders’ equity | |
| 223,836 | |
| 218,902 |
Total liabilities and stockholders’ equity | | $ | 279,668 | | $ | 273,942 |
Tactile Systems Technology, Inc. | ||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||
(Unaudited) | ||||||||||||
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
(In thousands, except share and per share data) | | 2026 | | 2025 | | 2026 | | 2025 | ||||
Revenue | | | | | | | | | | | | |
Sales revenue | | $ | 76,489 | | $ | 70,531 | | $ | 143,455 | | $ | 123,000 |
Rental revenue | |
| 9,209 | |
| 8,374 | |
| 17,510 | |
| 17,173 |
Total revenue | |
| 85,698 | |
| 78,905 | |
| 160,965 | |
| 140,173 |
Cost of revenue | | | | | | | | | | | | |
Cost of sales revenue | |
| 17,628 | |
| 17,483 | |
| 32,887 | |
| 31,374 |
Cost of rental revenue | |
| 2,721 | |
| 2,629 | |
| 5,115 | |
| 4,660 |
Total cost of revenue | |
| 20,349 | |
| 20,112 | |
| 38,002 | |
| 36,034 |
Gross profit | | | | | | | | | | | | |
Gross profit - sales revenue | |
| 58,861 | |
| 53,048 | |
| 110,568 | |
| 91,626 |
Gross profit - rental revenue | |
| 6,488 | |
| 5,745 | |
| 12,395 | |
| 12,513 |
Gross profit | |
| 65,349 | |
| 58,793 | |
| 122,963 | |
| 104,139 |
Operating expenses | | | | | | | | | | | | |
Sales and marketing | |
| 32,012 | |
| 30,039 | |
| 64,744 | |
| 57,555 |
Research and development | |
| 2,501 | |
| 2,018 | |
| 5,277 | |
| 3,759 |
Reimbursement, general and administrative | |
| 23,360 | |
| 22,034 | |
| 46,404 | |
| 42,032 |
Intangible asset amortization and earn-out | | | 650 | | | 619 | | | 1,246 | | | 1,252 |
Total operating expenses | |
| 58,523 | |
| 54,710 | |
| 117,671 | |
| 104,598 |
Income (loss) from operations | |
| 6,826 | |
| 4,083 | |
| 5,292 | |
| (459) |
Interest income | | | 561 | | | 850 | | | 1,227 | | | 1,745 |
Interest expense | | | (19) | | | (410) | | | (47) | | | (834) |
Other income | |
| — | |
| 1 | |
| — | |
| 1 |
Income before income taxes | |
| 7,368 | |
| 4,524 | |
| 6,472 | |
| 453 |
Income tax (benefit) expense | |
| (417) | |
| 1,307 | |
| 450 | |
| 210 |
Net income | | $ | 7,785 | | $ | 3,217 | | $ | 6,022 | | $ | 243 |
Net income per common share | | | | | | | | | | | | |
Basic | | $ | 0.34 | | $ | 0.14 | | $ | 0.27 | | $ | 0.01 |
Diluted | | $ | 0.34 | | $ | 0.14 | | $ | 0.26 | | $ | 0.01 |
Weighted-average common shares used to compute net income per common share | | | | | | | | | | | | |
Basic | | | 22,676,673 | | | 23,092,469 | | | 22,620,546 | | | 23,399,848 |
Diluted | | | 23,058,902 | | | 23,237,671 | | | 23,135,040 | | | 23,679,220 |
Tactile Systems Technology, Inc. | ||||||
Condensed Consolidated Statements of Cash Flows | ||||||
(Unaudited) | ||||||
| | | ||||
| | Six Months Ended June 30, | ||||
(In thousands) | | 2026 | | 2025 | ||
Cash flows from operating activities | | | | | | |
Net income | | $ | 6,022 | | $ | 243 |
Adjustments to reconcile net income to net cash provided by operating activities: | | | | | | |
Depreciation and amortization | | | 3,450 | | | 3,385 |
Deferred income taxes | | | 42 | | | (22) |
Stock-based compensation expense | | | 4,040 | | | 4,005 |
Loss on disposal of property and equipment and intangibles | | | 73 | | | 68 |
Changes in assets and liabilities, net of acquisition: | | | | | | |
Accounts receivable, net | | | 755 | | | 11,851 |
Net investment in leases | | | 827 | | | 83 |
Inventories | | | (2,820) | | | 1,555 |
Income taxes payable | | | (2,245) | | | (611) |
Prepaid expenses and other assets | | | (5,174) | | | (4,735) |
Right of use operating lease assets | | | (351) | | | (289) |
Accounts payable | | | 2,886 | | | 2,319 |
Accrued payroll and related taxes | | | (3,763) | | | (5,245) |
Accrued expenses and other liabilities | | | (827) | | | 2,567 |
Net cash provided by operating activities | | | 2,915 | | | 15,174 |
Cash flows from investing activities | | | | | | |
Payments related to acquisition, net of cash acquired | | | (6,226) | | | — |
Purchases of property and equipment | | | (2,102) | | | (748) |
Intangible assets expenditures | | | (52) | | | (56) |
Payment for exclusive distribution agreement | | | (3,000) | | | — |
Net cash used in investing activities | | | (11,380) | | | (804) |
Cash flows from financing activities | | | | | | |
Payments on note payable | | | — | | | (1,500) |
Proceeds from exercise of common stock options | | | 197 | | | 10 |
Proceeds from the issuance of common stock from the employee stock purchase plan | | | 1,032 | | | 843 |
Payments for repurchases of common stock | | | (6,357) | | | (26,562) |
Net cash used in financing activities | | | (5,128) | | | (27,209) |
Net decrease in cash | | | (13,593) | | | (12,839) |
Cash – beginning of period | | | 83,446 | | | 94,367 |
Cash – end of period | | $ | 69,853 | | $ | 81,528 |
| | | | | | |
Supplemental cash flow disclosure | | | | | | |
Cash paid for interest | | $ | 34 | | $ | 828 |
Cash paid for taxes | | $ | 2,645 | | $ | 892 |
Accrued excise tax on stock repurchases | | $ | — | | $ | 210 |
Capital expenditures incurred but not yet paid | | $ | 147 | | $ | 58 |
The following table summarizes revenue by product line for the three and six months ended June 30, 2026 and 2025:
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
(In thousands) | | 2026 | | 2025 | | 2026 | | 2025 | ||||
Revenue | | | | | | | | | | | | |
Lymphedema products | | $ | 73,630 | | $ | 65,969 | | $ | 135,851 | | $ | 116,524 |
Airway clearance products | | | 12,068 | | | 12,936 | | | 25,114 | | | 23,649 |
Total | | $ | 85,698 | | $ | 78,905 | | $ | 160,965 | | $ | 140,173 |
| | | | | | | | | | | | |
Percentage of total revenue | | | | | | | | | | | | |
Lymphedema products | |
| 86% | |
| 84% | |
| 84% | |
| 83% |
Airway clearance products | | | 14% | | | 16% | | | 16% | | | 17% |
Total | |
| 100% | |
| 100% | |
| 100% | |
| 100% |
The following table contains a reconciliation of net income to Adjusted EBITDA for the three and six months ended June 30, 2026 and 2025, as well as the dollar and percentage change between the comparable periods:
Tactile Systems Technology, Inc. | ||||||||||||||||||||||||
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA | ||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Increase | | Six Months Ended | | Increase | ||||||||||||||||
| | June 30, | | (Decrease) | | June 30, | | (Decrease) | ||||||||||||||||
(Dollars in thousands) | | 2026 | | 2025 | | $ | | % | | 2026 | | 2025 | | $ | | % | ||||||||
Net income |
| $ | 7,785 | | $ | 3,217 | | $ | 4,568 |
| 142 | % | | $ | 6,022 | | $ | 243 | | $ | 5,779 |
| N.M. | % |
Interest (income) expense, net | | | (542) | | | (440) | | | (102) |
| 23 | % | | | (1,180) | | | (911) | | | (269) |
| 30 | % |
Income tax (benefit) expense | | | (417) | | | 1,307 | | | (1,724) |
| (132) | % | | | 450 | | | 210 | | | 240 |
| 114 | % |
Depreciation and amortization | | | 1,811 | | | 1,659 | | | 152 |
| 9 | % | | | 3,450 | | | 3,385 | | | 65 |
| 2 | % |
Stock-based compensation | | | 2,260 | | | 1,939 | | | 321 |
| 17 | % | | | 4,040 | | | 4,005 | | | 35 |
| 1 | % |
Acquisition & integration costs | | | 156 | | | — | | | 156 | | — | % | | | 973 | | | — | | | 973 | | — | % |
Litigation-related costs | | | — | | | — | | | — | | — | % | | | 1,000 | | | — | | | 1,000 | | — | % |
Executive transition costs | | | 360 | | | — | | | 360 | | — | % | | | 360 | | | 491 | | | (131) | | (27) | % |
Adjusted EBITDA | | $ | 11,413 | | $ | 7,682 | | $ | 3,731 |
| 49 | % | | $ | 15,115 | | $ | 7,423 | | $ | 7,692 |
| 104 | % |
“N.M.” Not Meaningful
The following table contains a reconciliation of net income to Adjusted EBITDA for the year ended December 31, 2025:
Tactile Systems Technology, Inc. | |||
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA | |||
(Unaudited) | |||
| | | |
| | Year Ended | |
(Dollars in thousands) | | December 31, 2025 | |
Net income |
| $ | 19,086 |
Interest (income) expense, net | | | (2,059) |
Income tax expense | | | 12,253 |
Depreciation and amortization | | | 6,644 |
Stock-based compensation | | | 8,357 |
Executive transition costs | | | 491 |
Adjusted EBITDA | | $ | 44,772 |
The following table contains a reconciliation of GAAP net income guidance range to the Adjusted EBITDA guidance range for the twelve months ending December 31, 2026:
Tactile Systems Technology, Inc. | ||||||
Reconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance | ||||||
(Unaudited) | ||||||
| | | | | | |
| | Year Ended | ||||
| | December 31, 2026 | ||||
(Dollars in thousands) | | Low | | High | ||
Net income |
| $ | 23,230 | | $ | 24,670 |
Interest (income) expense, net | | | (2,380) | | | (2,380) |
Income tax expense | | | 9,420 | | | 9,980 |
Depreciation and amortization | | | 7,510 | | | 7,510 |
Stock-based compensation | | | 8,550 | | | 8,550 |
Acquisition & integration costs | | | 1,310 | | | 1,310 |
Executive transition costs | | | 360 | | | 360 |
Litigation-related costs | | | 1,000 | | | 1,000 |
Adjusted EBITDA | | $ | 49,000 | | $ | 51,000 |
Investor Inquiries:
Sam Bentzinger
Gilmartin Group